September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Twelve years incidence of open-angle glaucoma in the Thessaloniki Eye Study
Author Affiliations & Notes
  • Fotis Topouzis
    Department of Ophthalmology, School of Medicine, Aristotle University of Thessaloniki , Thessaloniki, Greece
  • M Roy Wilson
    Wayne State University, Detroit, Michigan, United States
  • Alon Harris
    Indiana University School of Medicine, Indianapolis, Indiana, United States
  • Panayiota Founti
    Department of Ophthalmology, School of Medicine, Aristotle University of Thessaloniki , Thessaloniki, Greece
    Moorfields Eye Hospital , London, United Kingdom
  • Fei Yu
    Stein Eye Institute, University of California Los Angeles (UCLA), Los Angeles, California, United States
    Department of Biostatistics, Fielding School of Public Health, University of California Los Angeles (UCLA), Los Angeles, California, United States
  • Theofanis Pappas
    Department of Ophthalmology, School of Medicine, Aristotle University of Thessaloniki , Thessaloniki, Greece
  • Eleftherios Anastasopoulos
    Department of Ophthalmology, School of Medicine, Aristotle University of Thessaloniki , Thessaloniki, Greece
  • Angeliki Salonikiou
    Department of Ophthalmology, School of Medicine, Aristotle University of Thessaloniki , Thessaloniki, Greece
  • Vassilis Kilintzis
    Department of Ophthalmology, School of Medicine, Aristotle University of Thessaloniki , Thessaloniki, Greece
  • Anne L Coleman
    Stein Eye Institute, University of California Los Angeles (UCLA), Los Angeles, California, United States
    Department of Epidemiology, Fielding School of Public Health, University of California Los Angeles (UCLA), Los Angeles, California, United States
  • Footnotes
    Commercial Relationships   Fotis Topouzis, Alcon (C), Alcon (F), Alcon (R), Allergan (C), Bausch & Lomb (C), Bayer (C), Humphrey Zeiss (C), Novartis (F), Novartis (C), Pfizer (F), Santen (R), Thea (C), Thea (F); M Roy Wilson, None; Alon Harris, AdOM (I), AdOM (C), Biolight (C), Isama therapeutics (C), Nano Retina (C), Ono (C), Oxymap (I), Science Based Health (C), Stemnion Inc (C); Panayiota Founti, None; Fei Yu, None; Theofanis Pappas, None; Eleftherios Anastasopoulos, None; Angeliki Salonikiou, None; Vassilis Kilintzis, None; Anne Coleman, None
  • Footnotes
    Support  This research has been co‐financed by the European Union (European Social Fund – ESF) and Greek national funds through the Operational Program "Education and Lifelong Learning" of the National Strategic Reference Framework (NSRF) ‐ Research Funding Program: THALES. Investing in knowledge society through the European Social Fund.
Investigative Ophthalmology & Visual Science September 2016, Vol.57, No Pagination Specified. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Fotis Topouzis, M Roy Wilson, Alon Harris, Panayiota Founti, Fei Yu, Theofanis Pappas, Eleftherios Anastasopoulos, Angeliki Salonikiou, Vassilis Kilintzis, Anne L Coleman; Twelve years incidence of open-angle glaucoma in the Thessaloniki Eye Study. Invest. Ophthalmol. Vis. Sci. 201657(12):.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To determine incidence rates of open-angle glaucoma (OAG), including primary open-angle glaucoma (POAG) and pseudoexfoliative glaucoma (PEXG), in the Thessaloniki Eye Study (TES) population.

Methods : This is a population-based incidence study. A total of 2554 randomly selected, Caucasian subjects, ≥60 years old participated in the TES prevalence study between 1999 and 2002. Participants were re-invited to undergo a comprehensive ophthalmic examination during the incidence study between 2013 and 2015. Definitions for OAG, POAG and PEXG in the incidence study were the same as in the prevalence study (Topouzis F, et al. Prevalence of open-angle glaucoma in Greece: the Thessaloniki Eye Study. Am J Ophthalmol. 2007;144:511-9).

Results : Among 2554 subjects who participated in the TES prevalence study, 1041 were deceased, 25 had moved and for 20 subjects no contact information was available. The remaining 1468 subjects for whom contact data were confirmed were deemed eligible to participate in the incidence study. All of the 1468 subjects were invited and 1092 were examined (participation rate 74.4%). The mean age at baseline was 68.9 ± 4.6 years with 566 males (51.8%) and 526 (48.8%) females. The mean follow-up time was 11.6 ± 1.6 years.
Among the 1092 participants, 45 subjects had been already diagnosed with OAG at baseline, leaving a total of 1047 participants at risk for OAG in the incidence study. Among them, there were 46 incident cases of OAG (30 males and 16 females, 65.2% and 34.8% respectively), corresponding to an incidence rate of 4.4%. Among these 46 incident cases of OAG, 22 were POAG and 24 were PEXG, corresponding to incident rates of 2.1% and 2.3% respectively.

Conclusions : In the TES population the twelve-year incidence rate for OAG is 4.4%, which appears to be higher than the 5 year OAG incidence rate reported by Rotterdam when extrapolated to the 12-year incidence. (de Voogd S, et al. Incidence of open-angle glaucoma in a general elderly population: the Rotterdam Study. Ophthalmology. 2005;112:1487-93).

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×